Lv31
330 积分 2022-08-31 加入
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
5小时前
待确认
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
5小时前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
1个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
4个月前
已关闭
The impact of the COVID-19 pandemic on socio-economic and sustainability
5个月前
已完结
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan
7个月前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
7个月前
已完结
DX-8951F, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant
7个月前
已完结
Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer
7个月前
已完结
Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy
7个月前
已完结
皖公网安备34019202002308
